ES2123062T3 - Polipeptidos de transporte derivados de la proteina tat. - Google Patents
Polipeptidos de transporte derivados de la proteina tat.Info
- Publication number
- ES2123062T3 ES2123062T3 ES93920231T ES93920231T ES2123062T3 ES 2123062 T3 ES2123062 T3 ES 2123062T3 ES 93920231 T ES93920231 T ES 93920231T ES 93920231 T ES93920231 T ES 93920231T ES 2123062 T3 ES2123062 T3 ES 2123062T3
- Authority
- ES
- Spain
- Prior art keywords
- absence
- tat protein
- transportation
- tat
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 101710149951 Protein Tat Proteins 0.000 title abstract 2
- -1 AMINO Chemical class 0.000 abstract 2
- 208000010444 Acidosis Diseases 0.000 abstract 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 abstract 1
- 108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 abstract 1
- 230000002776 aggregation Effects 0.000 abstract 1
- 238000004220 aggregation Methods 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 210000000805 cytoplasm Anatomy 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0065—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
- C12Y111/01—Peroxidases (1.11.1)
- C12Y111/01007—Peroxidase (1.11.1.7), i.e. horseradish-peroxidase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Abstract
ESTE INVENTO SE REFIERE A LA LIBERACION DE MOLECULAS DE CARGA BIOLOGICAMENTE ACTIVA, TALES COMO POLIPEPTIDOS Y ACIDOS NUCLEICOS, EN EL CITOPLASMA Y EL NUCLEO DE CELULAS "IN VITRO" E "IN VIVO", MEDIANTE EL EMPLEO DE NUEVOS POLIPEPTIDOS DE TRANSPORTE QUE COMPRENDEN UNA O MAS PARTES DE PROTEINA TAT DE HIV Y QUE ESTAN ENLAZADOS CONVALENTEMENTE A MOLECULAS DE CARGA. LOS POLIPEPTIDOS DE TRANSPORTE DE ESTE INVENTO SE CARACTERIZAN POR LA PRESENCIA DE LA REGION BASICA SALIENTE (AMINO ACIDOS 49 - 57), LA AUSENCIA DE REGION RICA EN CISTEINA SALIENTE (AMINO ACIDOS 22 - 36) Y LA AUSENCIA DEL DOMINIO DE TERMINAL CARBOXI CODIFICADO - 2 EXON TAT (AMINO ACIDOS 73 - 86) DE LA PROTEINA TAT QUE SE PRESENTA NATURALMENTE. LA AUSENCIA DE LA REGION RICA EN CISTEINA ENCONTRADA EN PROTEINAS TAT CONVENCIONALES RESUELVE LOS PROBLEMAS DE TRANSACTIVACION ESPUREA Y AGREGACION DE DISULFURO.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US93437592A | 1992-08-21 | 1992-08-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2123062T3 true ES2123062T3 (es) | 1999-01-01 |
Family
ID=25465458
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES93920231T Expired - Lifetime ES2123062T3 (es) | 1992-08-21 | 1993-08-19 | Polipeptidos de transporte derivados de la proteina tat. |
Country Status (14)
Country | Link |
---|---|
EP (3) | EP0656950B1 (es) |
JP (2) | JP2702285B2 (es) |
KR (1) | KR0153027B1 (es) |
AT (1) | ATE173016T1 (es) |
AU (1) | AU667244B2 (es) |
CA (1) | CA2135642C (es) |
DE (2) | DE69321962T2 (es) |
DK (1) | DK0656950T3 (es) |
ES (1) | ES2123062T3 (es) |
FI (1) | FI120495B (es) |
HK (1) | HK1012678A1 (es) |
NO (1) | NO316761B1 (es) |
NZ (1) | NZ255831A (es) |
WO (1) | WO1994004686A1 (es) |
Families Citing this family (114)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5219990A (en) * | 1991-01-28 | 1993-06-15 | Biogen, Inc. | Papillomavirus e2 trans-activation repressors |
US5861161A (en) * | 1994-09-07 | 1999-01-19 | Universite De Montreal | Chimeric proteins comprising a Vpr/Vpx virion incorporation domain for targeting into HIV-1 or HIV-2 virions |
US5955593A (en) * | 1996-09-09 | 1999-09-21 | Washington University | BH3 interacting domain death agonist |
JP2001511011A (ja) | 1997-01-21 | 2001-08-07 | ヒューマン ジノーム サイエンシーズ,インコーポレイテッド | 腫瘍壊死因子レセプター−1誘導性アポトーシスおよびcd−95誘導性アポトーシスの新規なインヒビターである、i−flice |
GB2341390B (en) | 1997-05-21 | 2000-11-08 | Univ Leland Stanford Junior | Composition and method for enhancing transport across biological membranes |
ES2326848T3 (es) | 1997-06-06 | 2009-10-20 | The Regents Of The University Of California | Inhibidores de la actividad de secuencias inmunoestimulatorias de adn. |
GB9720585D0 (en) * | 1997-09-26 | 1997-11-26 | Smithkline Beecham Biolog | Vaccine |
US6589503B1 (en) | 1998-06-20 | 2003-07-08 | Washington University | Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy |
US8038984B2 (en) | 1998-06-20 | 2011-10-18 | Washington University | Membrane-permeant peptide complexes for treatment of sepsis |
US7306784B2 (en) | 1998-06-20 | 2007-12-11 | Washington University | Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy |
WO1999067284A2 (en) * | 1998-06-20 | 1999-12-29 | Washington University | Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy |
EP1140202A1 (en) * | 1998-12-24 | 2001-10-10 | Ucb S.A. | Peptidic product, process and composition |
DE19916224C1 (de) * | 1999-04-10 | 2000-06-21 | November Ag Molekulare Medizin | Synthetisches biologisch aktives Molekül |
US6730293B1 (en) | 1999-08-24 | 2004-05-04 | Cellgate, Inc. | Compositions and methods for treating inflammatory diseases of the skin |
US6669951B2 (en) | 1999-08-24 | 2003-12-30 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into epithelial tissues |
JP2003507438A (ja) | 1999-08-24 | 2003-02-25 | セルゲイト, インコーポレイテッド | オリゴアルギニン部分を使用する上皮組織を横切るおよび上皮組織内への薬物送達の増強 |
US7229961B2 (en) | 1999-08-24 | 2007-06-12 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into ocular tissues |
US6881825B1 (en) | 1999-09-01 | 2005-04-19 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Identication of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and virues |
US20030108539A1 (en) * | 2000-02-14 | 2003-06-12 | Christophe Bonny | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
US8183339B1 (en) | 1999-10-12 | 2012-05-22 | Xigen S.A. | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
US6610820B1 (en) * | 1999-10-12 | 2003-08-26 | University Of Lausanne | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
US20040082509A1 (en) | 1999-10-12 | 2004-04-29 | Christophe Bonny | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
WO2001049832A2 (en) * | 2000-01-07 | 2001-07-12 | Artemis Pharmaceuticals Gmbh | Transduction of recombinases for inducible gene targeting |
EP2364734B1 (en) | 2000-07-21 | 2017-09-06 | ReVance Therapeutics, Inc. | Multi-component biological transport systems |
KR100379577B1 (ko) * | 2000-07-26 | 2003-04-08 | 최수영 | 세포침투성 티에이티 - 인간 글루탐산 탈수소효소 융합단백질, 이 융합단백질을 코딩하는 재조합폴리뉴클레오타이드, 이 융합단백질의 발현벡터 및 이융합단백질을 세포 내로 도입하는 방법 |
KR100379578B1 (ko) * | 2000-07-26 | 2003-04-08 | 최수영 | 세포침투성 티에이티-씨3 트랜스페라제 융합단백질, 이융합단백질의 발현벡터 및 티에이티-씨3 트랜스페라제를이용한 로 단백질의 생리적 기능 분석방법 |
ATE448301T1 (de) | 2000-09-08 | 2009-11-15 | Univ Zuerich | Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten |
US20050059031A1 (en) | 2000-10-06 | 2005-03-17 | Quantum Dot Corporation | Method for enhancing transport of semiconductor nanocrystals across biological membranes |
JP2005508832A (ja) | 2001-02-16 | 2005-04-07 | セルゲイト, インコーポレイテッド | 間隔を開けてアルギニン部分を含むトランスポーター |
EP1403365B1 (en) | 2001-06-05 | 2009-05-27 | Masahiro Hiraoka | Polypeptide unstabilizing protein in cells under aerobic conditions and dna encoding the same |
KR100495138B1 (ko) * | 2001-07-31 | 2005-06-14 | 학교법인 한림대학교 | 식물세포 투과 도메인-화물분자 복합체 |
ATE509120T1 (de) | 2001-09-18 | 2011-05-15 | Carnegie Inst Of Washington | Fusionsproteine zur detektion von analyten |
AU2002356824A1 (en) * | 2001-10-19 | 2003-05-06 | The Scripps Research Institute | Novel methods for introducing molecules into cells and vectors and compositions for use in such methods |
CA2471762C (en) | 2002-01-09 | 2010-08-17 | University Of Lausanne | Cell-permeable peptide inhibitors of the jnk signal transduction pathway |
US7026166B2 (en) | 2002-01-22 | 2006-04-11 | Chiron Corporation | Fluorogenic dyes |
WO2003086470A2 (en) * | 2002-04-17 | 2003-10-23 | Deutsches Krebsforschungszentrum | Smac-peptides as therapeutics against cancer and autoimmune diseases |
EP1354953A1 (en) * | 2002-04-17 | 2003-10-22 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Smac-peptides as therapeutics against cancer and autoimmune diseases |
WO2003089457A2 (en) | 2002-04-22 | 2003-10-30 | The Board Of Trustees Of The Leland Stanford Junior University | Peptide inhibitors of protein kinase c ϝ for pain management |
KR100472939B1 (ko) * | 2002-05-24 | 2005-03-18 | 학교법인 한림대학교 | 세포침투성 티에이티-피리독살 카이네이즈 융합단백질 및그 용도 |
CA2493674A1 (en) | 2002-07-19 | 2004-01-29 | The Regents Of The University Of California | Dendrimers as molecular translocators |
KR100472938B1 (ko) * | 2002-10-31 | 2005-03-11 | 학교법인 한림대학교 | 세포침투 효율을 향상시킨 수송도메인-목표단백질-수송도메인 융합단백질 및 그 용도 |
US7704756B2 (en) | 2003-01-21 | 2010-04-27 | Novartis Vaccines And Diagnostics, Inc. | Fluorogenic dyes |
ES2500921T3 (es) | 2003-04-29 | 2014-10-01 | Sarepta Therapeutics, Inc. | Composiciones para potenciar el transporte y la eficacia antisentido de análogos de ácidos nucleicos en células |
JPWO2005035562A1 (ja) * | 2003-10-07 | 2007-11-22 | 伸弥 山中 | 新規な細胞増殖促進剤 |
US7700737B2 (en) | 2003-12-05 | 2010-04-20 | Multimmune Gmbh | Therapeutic and diagnostic anti-Hsp70 antibodies |
WO2005120546A2 (en) | 2004-03-03 | 2005-12-22 | Essentia Biosystems, Inc. | Compositions and methods for topical diagnostic and therapeutic transport |
US9211248B2 (en) | 2004-03-03 | 2015-12-15 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
US20050288246A1 (en) | 2004-05-24 | 2005-12-29 | Iversen Patrick L | Peptide conjugated, inosine-substituted antisense oligomer compound and method |
JP4474264B2 (ja) * | 2004-08-20 | 2010-06-02 | 生寶生物科技股▲ふん▼有限公司 | 子宮頸癌抑制の融合蛋白 |
EP2314308A1 (en) | 2004-09-21 | 2011-04-27 | BioNTech AG | Use of microproteins as tryptase inhibitors |
JP4596391B2 (ja) | 2005-02-10 | 2010-12-08 | 国立大学法人大阪大学 | 細胞透過性ペプチド |
DK1988167T3 (da) | 2005-02-17 | 2020-07-13 | Univ Sorbonne | Intracellulære inhiberende peptider |
ATE507236T1 (de) | 2005-03-03 | 2011-05-15 | Revance Therapeutics Inc | Zusammensetzungen und methoden zur topischen anwendung und zur transdermalen verabreichung eines oligopeptids |
KR20070110402A (ko) | 2005-03-03 | 2007-11-16 | 레반스 테라퓨틱스 | 보툴리눔 독소의 국소 적용 및 경피 전달을 위한 조성물 및방법 |
EP1861417B1 (en) | 2005-03-10 | 2013-05-15 | BioNTech AG | Dimeric or multimeric microproteins |
KR100699279B1 (ko) | 2005-04-28 | 2007-03-23 | 학교법인 포항공과대학교 | 당 또는 당 유사체를 골격으로 하는 분자 수송체 및 그의제조방법 |
US7973084B2 (en) | 2005-04-28 | 2011-07-05 | Postech Academy-Industrial Foundation | Molecular transporters based on alditol or inositol and processes for the preparation thereof |
US8067571B2 (en) | 2005-07-13 | 2011-11-29 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
WO2007031098A1 (en) | 2005-09-12 | 2007-03-22 | Xigen S.A. | Cell-permeable peptide inhibitors of the jnk signal transduction pathway |
US8080517B2 (en) | 2005-09-12 | 2011-12-20 | Xigen Sa | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
CA3065947C (en) | 2005-10-18 | 2023-03-07 | National Jewish Health | Conditionally immortalized long-term stem cells and methods of making and using such cells |
US7517959B2 (en) | 2005-11-11 | 2009-04-14 | Walter And Eliza Hall Institute Of Medical Research | SOCS3 proteins |
KR101735257B1 (ko) | 2007-01-05 | 2017-05-12 | 유니버시티 오브 취리히 | 질환 특이적 결합 분자 및 표적을 제공하는 방법 |
WO2008112922A2 (en) | 2007-03-13 | 2008-09-18 | National Jewish Medical And Research Center | Methods for generation of antibodies |
WO2008110372A1 (en) | 2007-03-13 | 2008-09-18 | University Of Zurich | Monoclonal human tumor-specific antibody |
US20110038865A1 (en) | 2007-06-26 | 2011-02-17 | University Of Miami | Antibody- endostatin fusion protein and its variants |
US20100016215A1 (en) | 2007-06-29 | 2010-01-21 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
CN102872447B (zh) | 2007-07-26 | 2015-09-30 | 雷文斯治疗公司 | 抗微生物肽,组合物和使用方法 |
EP2185592B1 (en) | 2007-09-13 | 2013-01-23 | University Of Zurich Prorektorat Forschung | Monoclonal amyloid beta (abeta)-specific antibody and uses thereof |
US7935816B2 (en) | 2007-10-25 | 2011-05-03 | Gene Tools, Llc | Molecular transporter compositions comprising dendrimeric oligoguanidine with a triazine core that facilitate delivery into cells in vivo |
AU2009218060B2 (en) | 2008-02-28 | 2014-08-28 | Toray Industries, Inc. | Pharmaceutical composition for transnasal administration |
WO2009139930A2 (en) | 2008-05-16 | 2009-11-19 | Taiga Biotechnologies, Inc. | Antibodies and processes for preparing the same |
WO2009143865A1 (en) | 2008-05-30 | 2009-12-03 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
WO2009143864A1 (en) | 2008-05-30 | 2009-12-03 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases |
US9169462B2 (en) | 2008-07-21 | 2015-10-27 | Taiga Biotechnologies, Inc. | Methods for preparing mature erythrocytes from conditionally immortalized hematopoietic stem cells |
AU2009279682B2 (en) | 2008-08-04 | 2015-01-22 | University Of Miami | STING (stimulator of interferon genes), a regulator of innate immune responses |
US8784825B2 (en) | 2008-08-28 | 2014-07-22 | Taiga Biotechnologies, Inc. | Modulators of MYC, methods of using the same, and methods of identifying agents that modulate MYC |
WO2010072228A1 (en) * | 2008-12-22 | 2010-07-01 | Xigen S.A. | Novel transporter constructs and transporter cargo conjugate molecules |
EP2433953B1 (en) | 2009-05-20 | 2015-07-08 | Toray Industries, Inc. | Cell membrane-permeable peptides |
EP3252068A3 (en) | 2009-10-12 | 2018-03-14 | Larry J. Smith | Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro |
WO2011160653A1 (en) | 2010-06-21 | 2011-12-29 | Xigen S.A. | Novel jnk inhibitor molecules |
EP2618829B1 (en) | 2010-09-22 | 2019-05-01 | The Regents of the University of Colorado, a body corporate | Smad7 for use in the treatment of oral mucositis or psoriasis |
CA2807036C (en) | 2010-10-14 | 2018-01-16 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases |
KR101614997B1 (ko) | 2011-01-10 | 2016-04-22 | 씨티 아틀란틱 엘티디. | 종양 관련 항원 결합 항체를 포함하는 조합 요법 |
JP6478632B2 (ja) | 2011-05-05 | 2019-03-06 | サレプタ セラピューティクス, インコーポレイテッド | ペプチドオリゴヌクレオチドコンジュゲート |
US9161948B2 (en) | 2011-05-05 | 2015-10-20 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
JP2014524891A (ja) | 2011-06-03 | 2014-09-25 | シーティー アトランティック リミテッド | Magea3結合抗体 |
EP2714742A1 (en) | 2011-06-03 | 2014-04-09 | CT Atlantic Ltd. | Magea3 binding antibodies |
DE202011103324U1 (de) | 2011-07-12 | 2012-01-02 | Nekonal S.A.R.L. | Therapeutische anti-TIRC7 Antikörper für die Verwendung in Immun und anderen Krankheiten |
WO2013091670A1 (en) | 2011-12-21 | 2013-06-27 | Xigen S.A. | Novel jnk inhibitor molecules for treatment of various diseases |
EP2794660A2 (en) | 2011-12-23 | 2014-10-29 | Phenoquest AG | Antibodies for the treatment and diagnosis of affective and anxiety disorders |
US9957319B2 (en) | 2011-12-28 | 2018-05-01 | Immunoqure Ag | Method of isolating human antibodies |
AU2013292330B2 (en) | 2012-07-20 | 2018-07-12 | Taiga Biotechnologies, Inc. | Enhanced reconstitution and autoreconstitution of the hematopoietic compartment |
SG11201507045TA (en) | 2013-03-08 | 2015-10-29 | Univ Colorado Regents | Ptd-smad7 therapeutics |
EP2968613B1 (en) | 2013-03-11 | 2019-09-11 | University of Florida Research Foundation, Inc. | Delivery of card protein as therapy for occular inflammation |
US10272115B2 (en) | 2013-03-11 | 2019-04-30 | Taiga Biotechnologies, Inc. | Production and use of red blood cells |
US9365825B2 (en) | 2013-03-11 | 2016-06-14 | Taiga Biotechnologies, Inc. | Expansion of adult stem cells in vitro |
AU2014301631A1 (en) * | 2013-06-26 | 2015-08-27 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases |
WO2014206427A1 (en) | 2013-06-26 | 2014-12-31 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
WO2015197097A1 (en) | 2014-06-26 | 2015-12-30 | Xigen Inflammation Ltd. | New use for jnk inhibitor molecules for treatment of various diseases |
CA2917112C (en) | 2013-07-03 | 2022-07-05 | Immunoqure Ag | Human anti-ifn-alpha antibodies |
AU2015229381B2 (en) | 2014-03-11 | 2019-11-07 | University Of Florida Research Foundation, Inc. | Use of AAV-expressed M013 protein as an anti-inflammatory therapeutic |
JP6468722B2 (ja) * | 2014-04-30 | 2019-02-13 | 日本信号株式会社 | 物体検出装置 |
AU2016273213B2 (en) | 2015-06-01 | 2019-03-14 | Medigene Immunotherapies Gmbh | T cell receptor library |
CA2987877A1 (en) | 2015-06-01 | 2016-12-08 | Medigene Immunotherapies Gmbh | T-cell receptor specific antibodies |
NZ737423A (en) | 2015-06-01 | 2019-08-30 | Medigene Immunotherapies Gmbh | Method for generating antibodies against t cell receptor |
WO2016196897A1 (en) | 2015-06-04 | 2016-12-08 | Sarepta Therapeutics, Inc. | Methods and compounds for treatment of lymphocyte-related diseases and conditions |
EP3309178A4 (en) | 2015-06-11 | 2019-05-08 | Keio University | FUSION PROTEIN OR CONJUGATED PROTEIN, CARRIER FOR INTRA-CELLULAR DELIVERY, PARTICLE PEPTIDE, CELL MEMBRANE PERMEATION AMPLIFIER, DNA AND VECTOR |
EP3901254A1 (en) | 2015-12-23 | 2021-10-27 | Medigene Immunotherapies GmbH | Novel generation of antigen-specific tcrs |
CN113786476A (zh) | 2016-12-02 | 2021-12-14 | 泰加生物工艺学公司 | 纳米颗粒调配物 |
RS63610B1 (sr) | 2016-12-19 | 2022-10-31 | Sarepta Therapeutics Inc | Oligomerni konjugati za preskakanje egzona za mišićnu distrofiju |
US10149898B2 (en) | 2017-08-03 | 2018-12-11 | Taiga Biotechnologies, Inc. | Methods and compositions for the treatment of melanoma |
WO2020066343A1 (ja) | 2018-09-26 | 2020-04-02 | 株式会社カネカ | 細胞膜透過性ペプチド |
JPWO2022154079A1 (es) * | 2021-01-18 | 2022-07-21 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0506884B1 (en) * | 1989-12-21 | 1996-09-04 | Whitehead Institute For Biomedical Research | Method of delivering molecules into eukaryotic cells |
US5219990A (en) | 1991-01-28 | 1993-06-15 | Biogen, Inc. | Papillomavirus e2 trans-activation repressors |
-
1993
- 1993-08-19 EP EP93920231A patent/EP0656950B1/en not_active Expired - Lifetime
- 1993-08-19 WO PCT/US1993/007833 patent/WO1994004686A1/en active IP Right Grant
- 1993-08-19 ES ES93920231T patent/ES2123062T3/es not_active Expired - Lifetime
- 1993-08-19 DK DK93920231T patent/DK0656950T3/da active
- 1993-08-19 DE DE69321962T patent/DE69321962T2/de not_active Expired - Lifetime
- 1993-08-19 JP JP6506542A patent/JP2702285B2/ja not_active Expired - Lifetime
- 1993-08-19 NZ NZ255831A patent/NZ255831A/en not_active IP Right Cessation
- 1993-08-19 AT AT93920231T patent/ATE173016T1/de active
- 1993-08-19 AU AU50832/93A patent/AU667244B2/en not_active Expired
- 1993-08-19 EP EP98105625A patent/EP0903408A3/en not_active Ceased
- 1993-08-19 EP EP08004968A patent/EP2000536A3/en not_active Withdrawn
- 1993-08-19 CA CA002135642A patent/CA2135642C/en not_active Expired - Lifetime
- 1993-08-19 DE DE0656950T patent/DE656950T1/de active Pending
-
1994
- 1994-11-08 FI FI945248A patent/FI120495B/fi not_active IP Right Cessation
- 1994-11-09 NO NO19944273A patent/NO316761B1/no not_active IP Right Cessation
- 1994-12-28 KR KR1019940704779A patent/KR0153027B1/ko not_active IP Right Cessation
-
1997
- 1997-04-14 JP JP9096264A patent/JP2869396B2/ja not_active Expired - Lifetime
-
1998
- 1998-12-17 HK HK98113962A patent/HK1012678A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
HK1012678A1 (en) | 1999-08-06 |
DE69321962D1 (de) | 1998-12-10 |
JPH07503617A (ja) | 1995-04-20 |
JPH1033186A (ja) | 1998-02-10 |
DE69321962T2 (de) | 1999-07-01 |
KR0153027B1 (en) | 1998-10-15 |
EP0656950B1 (en) | 1998-11-04 |
FI120495B (fi) | 2009-11-13 |
WO1994004686A1 (en) | 1994-03-03 |
JP2869396B2 (ja) | 1999-03-10 |
CA2135642C (en) | 1999-12-14 |
CA2135642A1 (en) | 1994-03-03 |
NZ255831A (en) | 1997-04-24 |
EP2000536A2 (en) | 2008-12-10 |
EP0903408A2 (en) | 1999-03-24 |
AU5083293A (en) | 1994-03-15 |
EP0656950A1 (en) | 1995-06-14 |
JP2702285B2 (ja) | 1998-01-21 |
NO944273L (no) | 1995-02-17 |
AU667244B2 (en) | 1996-03-14 |
NO316761B1 (no) | 2004-05-03 |
FI945248A0 (fi) | 1994-11-08 |
ATE173016T1 (de) | 1998-11-15 |
NO944273D0 (no) | 1994-11-09 |
DK0656950T3 (da) | 1999-07-19 |
EP0903408A3 (en) | 2005-11-02 |
EP2000536A3 (en) | 2010-06-30 |
DE656950T1 (de) | 1996-03-14 |
FI945248A (fi) | 1995-01-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2123062T3 (es) | Polipeptidos de transporte derivados de la proteina tat. | |
Maeshima et al. | Specific targeting of insect and vertebrate telomeres with pyrrole and imidazole polyamides | |
NO20001683L (no) | Peptid/lipid-kompleksdannelse ved samlyofilisering | |
EA200001125A1 (ru) | Гелеобразные фармацевтические композиции | |
BR9809910A (pt) | Peptìdeos lh-rh análogos, seus usos e composições farmacêuticas contendo-os | |
MX9305729A (es) | Formulas de proteinas de liberacion sostenida. | |
TR200102277T2 (tr) | Üç halkalı (Trisiklik) pirazol türevleri | |
DE69832631D1 (de) | Zusammensetzungen geeignet zur kontrollierten freisetzung des hormons gnrh und dessen analoga | |
Borgne-Sanchez et al. | Targeted Vpr-derived peptides reach mitochondria to induce apoptosis of αvβ3-expressing endothelial cells | |
DE69009476T2 (de) | Hemmung des reaktionswegs für die n-ende-regel in lebenden zellen. | |
ES2167939T3 (es) | Nuevas poliaminas, su preparacion y usos. | |
FR2860236A1 (fr) | Peptides possedant notamment une activite anti-angiogenique et leurs applications en therapeutique | |
ATE295727T1 (de) | Verwendung bestimmter substituierter pyrrolidone wie z.b. piracetam bei der behandlung von viralen und anderen erkrankungen | |
KR970706732A (ko) | 엘레우테로빈 및 그의 유사체(ELEUTHEROBlN AND ANALOGS THEREOF) | |
DK0906272T3 (da) | Peptider | |
ATE73821T1 (de) | Pyrrolidonderivate. | |
ES2129893T3 (es) | Dinucleosido-5',5'-pirofosfatos. | |
BR9712128A (pt) | Métodos e composições para lipidização de moléculas hidrofìlicas | |
DE69939586D1 (de) | Inhibitoren für die gefässneubildung | |
BR9813102A (pt) | Derivados de ácido metilenobisfosfÈnico novos | |
Paul et al. | Translocation of acylated pardaxin into cells | |
IT1251961B (it) | Peptidi che rappresentano permutazioni della sequenza del mastoparano | |
Yu et al. | Ca super (2+)-mediated GTP-dependent dynamic assembly of bacterial cell division protein FtsZ into asters and polymer networks in vitro | |
ES2127516T3 (es) | Peptidos para inhibir la liberacion de pepsina. | |
ATE308984T1 (de) | Arzneiformen zur behandlung von krankheiten, die auf aktivierung des ppar-gamma-rezeptors ansprechen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 656950 Country of ref document: ES |